162 related articles for article (PubMed ID: 24144311)
21. Optical neuropathy possibly related to arsenic during acute promyelocytic leukemia treatment.
Thery JC; Jardin F; Massy N; Massy J; Stamatoullas A; Tilly H
Leuk Lymphoma; 2008 Jan; 49(1):168-70. PubMed ID: 18203030
[No Abstract] [Full Text] [Related]
22. The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia.
Zhu H; Hu J; Chen L; Zhou W; Li X; Wang L; Zhao X; Zhang Y; Zhao H; Wang A; Chen Y; Sun H; Chen Q; Chen Y; Zhao W; Mi J; Shen Z; Wang Z; Chen Z; Chen S; Li J
Blood; 2016 Sep; 128(11):1525-8. PubMed ID: 27402972
[No Abstract] [Full Text] [Related]
23. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
24. Prolonged oral arsenic trioxide therapy and nephrolithiasis [corrected].
Au WY; Tam S; Fong BM; Ho KL; Tam PC; Kwong YL
Leuk Lymphoma; 2007 Nov; 48(11):2233-4. PubMed ID: 17926176
[No Abstract] [Full Text] [Related]
25. Hyperleukocytosis from arsenic trioxide.
Levy M; Wofford MM; Powell BL; McLean TW
Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
[TBL] [Abstract][Full Text] [Related]
26. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
Lengfelder E; Schultheis B; Büchner T; Hehlmann R
Dtsch Med Wochenschr; 2007 Feb; 132(7):330-6. PubMed ID: 17286223
[No Abstract] [Full Text] [Related]
27. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
28. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
29. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
Naito K; Kobayashi M; Sahara N; Shigeno K; Nakamura S; Shinjo K; Tobita T; Takeshita A; Ohno R; Ohnishi K
Int J Hematol; 2006 May; 83(4):318-23. PubMed ID: 16757431
[TBL] [Abstract][Full Text] [Related]
30. Herpes zoster during treatment with arsenic trioxide.
Lanska DJ
Ann Hematol; 2004 Jun; 83(6):408. PubMed ID: 15034759
[No Abstract] [Full Text] [Related]
31. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia.
Huang SY; Chang CS; Tang JL; Tien HF; Kuo TL; Huang SF; Yao YT; Chou WC; Chung CY; Wang CH; Shen MC; Chen YC
Br J Haematol; 1998 Dec; 103(4):1092-5. PubMed ID: 9886325
[TBL] [Abstract][Full Text] [Related]
32. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction.
Roberts TF; Sprague K; Schenkein D; Miller KB; Relias V
Blood; 2000 Dec; 96(12):4000-1. PubMed ID: 11186272
[No Abstract] [Full Text] [Related]
33. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
[No Abstract] [Full Text] [Related]
34. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
Hai JJ; Gill H; Tse HF; Kumana CR; Kwong YL; Siu CW
Ann Hematol; 2015 Mar; 94(3):501-3. PubMed ID: 25079038
[No Abstract] [Full Text] [Related]
35. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
36. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
[No Abstract] [Full Text] [Related]
37. Arsenic trioxide: applications, mechanisms of action, toxicity and rescue strategies to date.
Yan M; Wang H; Wei R; Li W
Arch Pharm Res; 2024 Mar; 47(3):249-271. PubMed ID: 38147202
[TBL] [Abstract][Full Text] [Related]
38. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
39. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
[TBL] [Abstract][Full Text] [Related]
40. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
